Senores Pharmaceuticals (SPL), through its wholly-owned subsidiary Senores Pharmaceuticals, Inc., USA, has signed an agreement to acquire the USFDA-approved Abbreviated New Drug Application (ANDA) for Tramadol Tablets from APDM Pharmaceuticals.

Tramadol is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate. The market size of Tramadol Tablets in the USA was ~USD 61.95 million (MAT December 2024) as per IQVIA and ~USD 119.09 Mn (MAT March 2025) as per the speciality data aggregator Symphony.

The acquisition will be funded through the Initial Public Offer (IPO) proceeds raised by SPL. This is in line with the objectives of the IPO stated in the Red Herring Prospectus.

Senores Pharmaceuticals is a global, research-driven pharmaceutical company engaged in developing and manufacturing a wide range of pharmaceutical products predominantly for the US, Canada, and other regulated and emerging markets across various therapeutic areas and dosage forms.

The companies’ current portfolio includes 61 ANDA and 22 CMO/CDMO commercial products that are permitted for distribution in the USA. Senores is also engaged in the development and manufacturing of complex generics certified by global food and drugs authorities and delivers generic drugs for emerging markets catering to more than 40 countries.

The company has currently approval from regulatory bodies of more than 10 countries for its manufacturing facility in Chhatral for emerging markets with over 260 product registrations and 530 product applications. Senores also manufactures critical care injectables and Active Pharmaceutical Ingredients (API).

Senores has 2 manufacturing facilities for formulations – one in Atlanta, US, which is USFDA approved and DEA/BAA compliant, and the other is in Chhatral, Ahmedabad, India, approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda.

Senores has 2 manufacturing facilities for formulations - one in Atlanta, US which is USFDA approved and DEA, TAA and BAA compliant for controlled substances and government supplies and the other is in Chhatral, Ahmedabad, India approved by WHO-GMP to cater to emerging markets. The company also has 2 manufacturing facilities for API in India, both located around Ahmedabad, with one in Chhatral and the other in Naroda. Senores has strong R&D capabilities to drive differentiated product portfolio across 3 R&D sites – 1 in the US and 2 in India.